Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POVAN vs EMVERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Treatment of enterobiasis (pinworm infection) caused by Enterobius vermicularis
Treatment of trichuriasis (whipworm infection),Treatment of enterobiasis (pinworm infection),Treatment of ascariasis (roundworm infection),Treatment of hookworm infections (Ancylostoma duodenale and Necator americanus),Off-label: Treatment of capillariasis, toxocariasis, and other helminth infections
Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Terminal elimination half-life is approximately 16 hours; clinically, this supports single-dose administration with slow elimination
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Pyrvinium pamoate is minimally absorbed from the gastrointestinal tract; systemic metabolism is negligible. The small absorbed fraction is metabolized in the liver, but specific enzymes are not well defined.
Primarily hepatic; metabolized by microsomal enzymes (CYP450) to major metabolite 2-aminomebendazole, which is less active; also undergoes further metabolism.
Primarily fecal (90%) as unchanged drug via bile; renal excretion is minimal (<1%)
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Bound to plasma proteins (especially albumin) approximately 75–80%
~90-95% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is 0.5–0.7 L/kg, consistent with moderate tissue distribution
~1-2 L/kg; indicates extensive tissue distribution.
Oral bioavailability is low (<10%) due to poor absorption; acts topically in the GI tract
Oral: ~22-40% due to first-pass metabolism; improved with food.
No specific guidelines; caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Contraindicated in acute hepatic disease or significant liver impairment (Child-Pugh class B or C); use not recommended.
No adjustment for mild (Child-Pugh A) or moderate (Child-Pugh B) impairment. Avoid use in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Weight-based: 11 mg/kg (maximum 1 g) orally once for pinworm; repeat in 2 weeks. For other infections: 11 mg/kg once daily for 3 days.
Children ≥2 years: 100 mg orally twice daily for 3 days. Children <2 years: safety not established; use only if potential benefit outweighs risk.
No specific adjustments; use standard dosing with caution due to potential comorbidities and reduced hepatic function.
No specific adjustment required; use standard adult dosing. Monitor for adverse effects due to potential age-related renal or hepatic decline.
None
None.
Gastrointestinal disturbances may occur; caution in patients with inflammatory bowel disease or severe hepatic impairment. May cause staining of stools and emesis. Avoid in pregnancy unless clearly needed.
Risk of neutropenia and agranulocytosis, especially with high doses or prolonged use,May cause bone marrow suppression; monitor blood counts in prolonged therapy,Hepatotoxicity reported; use caution in hepatic impairment,Seizures have occurred, particularly in patients with history of seizures,Not recommended in pregnancy (pregnancy category C); embryotoxic and teratogenic in animals
Hypersensitivity to pyrvinium or any component of the formulation,Intestinal obstruction or acute abdominal conditions
Hypersensitivity to mebendazole or any component of the formulation,Absolute contraindication: Known hypersensitivity
No specific food interactions. The drug should be taken with food to reduce gastrointestinal upset.
No significant food interactions; absorption is enhanced by fatty foods but not required for efficacy in enterobiasis. Avoid alcohol due to potential hepatotoxicity.
Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first trimester, avoid use unless clearly needed. Second and third trimester: consider risk-benefit; no known fetal harm from limited reports.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed. Risk cannot be ruled out, especially in the first trimester.
Unknown if pyrvinium pamoate is excreted in human milk. M/P ratio not available. Caution advised, consider alternative treatment during breastfeeding.
Excretion in human milk unknown. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
No dose adjustment studied in pregnancy. Standard adult dose: 5 mg/kg base (max 350 mg) single dose. Use only if potential benefit justifies risk.
No dose adjustment is recommended solely due to pregnancy, as pharmacokinetic changes are not well characterized. Use standard dosing: mebendazole 100 mg twice daily for 3 days for pinworm (or single 100 mg dose). For other indications, follow standard protocols.
POVAN (pyrvinium pamoate) is primarily used for enterobiasis (pinworm infection). Administer as a single oral dose; repeat after 2 weeks to prevent reinfection. Tablets should be swallowed whole to avoid staining teeth. Drug may turn stools red. Avoid in patients with gastrointestinal disorders or inflammatory bowel disease. Monitor for nausea, vomiting, and cramping.
EMVERM (mebendazole) is poorly absorbed systemically, making it ideal for intraluminal helminth infections. Administer with fatty meal to enhance absorption when systemic effect (e.g., for trichinosis) is desired. Avoid in pregnancy (FDA Category C). Tablets may be chewed, swallowed, or crushed. Monitor for rare agranulocytosis, especially with concurrent metronidazole or high doses.
Take the medication exactly as a single dose, and repeat after 2 weeks.,Swallow tablets whole; do not crush or chew to prevent mouth staining.,Stools may appear bright red; this is harmless.,Wash hands thoroughly after using the toilet and before eating to prevent reinfection.,Wash bedding and underwear in hot water; vacuum floors to remove eggs.,Treat all household members simultaneously to avoid spread.,Report persistent abdominal pain or diarrhea to your doctor.
Take exactly as prescribed; a second course may be needed if reinfection occurs.,Tablets can be chewed, crushed, or swallowed whole with or without food.,Mebendazole works by preventing worms from absorbing sugar, causing their death.,Strict hand hygiene and laundering of bedding/clothing to prevent reinfection.,Treat all household members if pinworm outbreak; withhold treatment in pregnancy unless essential.,Notify provider if fever, sore throat, or unusual bleeding/bruising (agranulocytosis warning).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POVAN vs EMVERM, answered by our medical review team.
POVAN is a Anthelmintic that works by Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.. EMVERM is a Anthelmintic that works by Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POVAN and EMVERM depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POVAN is: Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.. The standard adult dose of EMVERM is: Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POVAN and EMVERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POVAN is classified as Category C. Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first tr. EMVERM is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.